The increasing demand for different biologically active molecules has posed challenges to the scientists to get the desired substances in large amounts either from natural sources or to produce synthetically through efficient and economically viable routes.
Our company, OTAVA Ltd., provides a wide range of biologically active compounds modulating activity of distinct targets.
Protein kinases are popular targets in oncology drug development. These proteins are upregulated in tumor cells making them ideal targets for selective tumor therapy. Currently kinase inhibitors are among the most preferred drugs in development by many pharmaceutical companies. Our company offers a variety of inhibitors including CDK4, DNA-PK, EGFR, CK2, CDK2, IKK-ε, GSK-3 and JNK3 inhibitors. We also propose sets of compounds that inhibit Histone Deacetylase (HDAC), Cyclooxygenase-1, CFTR Chloride Channel, Hypoxia-Inducible Factor-1, STAT3 Transcription Factor, NAD-Dependent Deacetylases SIRT1 and SIRT2.
Protein-protein interactions have a key role in most biological processes and offer attractive opportunities for therapeutic intervention. Developing small molecules that modulate protein-protein interactions is difficult. There has been important progress in this endeavour in recent years. A recently developed inhibitior of interaction between the translation initiation factors eIF4E and eIF4G is commercially available from our company.
In addition to these highly valuable products, OTAVA offers compounds which were evaluated in vitro on 60 human tumor cell lines.
Our biologically active compounds can also be used in experimental biology for understanding the functions of biological molecules in vivo and some compounds could further be used in drug design.